Michael Davidson, CEO of NewAmsterdam Pharma Company N.V., presented data on obicetrapib at the ESC Congress on August 25, 2025, as part of investor conferences.
4 reports, 1 independent
Updated Aug 26
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Michael Davidson, CEO of NewAmsterdam Pharma Company N.V., presented data on obicetrapib at the ESC Congress on August 25, 2025, as part of investor conferences.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Michael Davidson
researcher (ORCID 0000-0002-0020-4578)
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireNewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company
- GlobeNewswireNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results –European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – –